Accueil > Actualité
Actualite financiere : Actualite bourse

Novartis: Europe recommends approving Zolgensma

( - A panel of the European medicines regulator has recommended approving Novartis' Zolgensma, currently the only gene therapy for spinal muscular atrophy (SMA).

The Swiss drugmaker's AveXis unit today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the product's conditional marketing authorisation.

SMA is a rare, genetic neuromuscular disease, affecting muscle functions, including breathing, swallowing and basic movements.

The CHMP has also adopted a positive opinion for Cosentyx for the treatment of adult patients with active non-radiographic axial spondyloarthritis, Novartis said.

Copyright (c) 2020 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.